Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825056 | 1.00 | CYP3A4 (0.31) | CYP3A4SLC7A5HRH4HRH3CYP1A2 | |
| SCHEMBL12825059 | 1.00 | CYP3A4 (0.31) | CYP3A4SLC7A5HRH4HRH3CYP1A2 | |
| SCHEMBL25586209 | 0.86 | — | — | |
| SCHEMBL18819943 | 0.86 | — | — | |
| SCHEMBL4170559 | 0.85 | CYP3A4 (0.32) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL23897440 | 0.84 | NOS2 (0.32) | NOS2 | |
| SCHEMBL18868737 | 0.84 | NOS2 (0.32) | NOS2 | |
| SCHEMBL12279581 | 0.83 | SLC7A5 (0.33) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL6338009 | 0.83 | SLC7A5 (0.33) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL12279297 | 0.83 | SLC7A5 (0.33) | CYP3A4SLC7A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968080-B1 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR | SYNEDGEN INC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2021221656-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-2897622-B1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION | SYNEDGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3311823-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | Synedgen, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-9738660-B2 | Selective inhibitors for protein kinases and pharmaceutical composition and use thereof | NATIONAL CHIAO TUNG UNIVERSITY (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9738660-B2 | Selective inhibitors for protein kinases and pharmaceutical composition and use thereof | NATIONAL CHIAO TUNG UNIVERSITY (CN) | 2017-08-22 | — | — | US | disclosed |
| EP-2473042-B1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160096848-A1 | SELECTIVE INHIBITORS FOR PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | NATIONAL CHIAO TUNG UNIVERSITY (CN) | 2016-04-07 | — | — | US | disclosed |
| US-9067967-B2 | Peptides useful in the treatment and care of the skin and mucous membranes and their use in cosmetic or pharmaceutical compositions | LIPOTEC, S.A. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20140120141-A1 | PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LIPOTEC S.A. (ES) | 2014-05-01 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | CYP3A4 1682/4885SLC7A5 4773/4885HRH4 3935/4885 |
| US-20160096848-A1 | SELECTIVE INHIBITORS FOR PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CSNK1A1, MAP3K1, PACSIN2 | CYP3A4 2764/4885SLC7A5 1394/4885HRH4 2440/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CYP3A4 1682/4885SLC7A5 4773/4885HRH4 3935/4885 |
| US-20140120141-A1 | PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | CUTA, MC1R, VIP | CYP3A4 4830/4885SLC7A5 1605/4885HRH4 930/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | CYP3A4 1682/4885SLC7A5 4773/4885HRH4 3935/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | CYP3A4 1682/4885SLC7A5 4773/4885HRH4 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.